Elotuzumab

Red

Brand Name(s):Empliciti

Indication:Multiple myeloma in adult patients who have received at least one prior therapy

Rationale:1,2,3

Considered:Jun-16

Review Date:Sep-24

Comments:
SPC updated to include extension of indication in relapsed and refractory multiple myeloma; Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1). Empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy (see sections 4.2 and 5.1).